Your institution may have access to this item. Find your institution then sign in to continue.
Title
Sirolimus to phase III trial for treating non-infectious posterior uveitis.
Abstract
The article focuses on a global phase III clinical study initiated by Santen Inc. to evaluate the safety and efficacy of three different doses of its investigational drug sirolimus (DE-109) for treating non-infectious posterior uveitis.